Actualités Aeterna Zentaris Inc - AEZS | Actions Toronto Stock Exchange

Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.

TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc...

Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders

TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS...

Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Company expects to report top-line data and complete study results in Q3 2024 TORONTO, ONTARIO, June 13, 2024...

Aeterna Zentaris and Ceapro Complete Merger Transaction

TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:...

Aeterna Zentaris and Ceapro Complete Merger Transaction

TORONTO and EDMONTON, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS...

Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date

TORONTO, ONTARIO, May 29, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS...

Aeterna Zentaris Announces Details Regarding Transaction with Ceapro

TORONTO, ON, May 17, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or...

Aeterna Zentaris Reports First Quarter 2024 Financial Results

Company ended the quarter with $29.5 million in cashDETECT-trial recruitment completed; Company continues to...

Aeterna Zentaris Announces Effective Date of Share Consolidation

TORONTO, ON, May 01, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or...

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:...

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the...

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

TORONTO and EDMONTON, Alberta, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:...

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

TORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS...

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

ISS states in its Aeterna Zentaris FOR recommendation that “on balance, the deal has strong strategic merit...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Aeterna Zentaris Inc (AEZS)

Votre Hub pour des idées et discussions en direct en temps réel

AEZS Actualités

Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.

Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders

Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Aeterna Zentaris and Ceapro Complete Merger Transaction

Aeterna Zentaris and Ceapro Complete Merger Transaction

Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date

Aeterna Zentaris Announces Details Regarding Transaction with Ceapro

Aeterna Zentaris Reports First Quarter 2024 Financial Results

Aeterna Zentaris Announces Effective Date of Share Consolidation

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Aeterna Zentaris Inc (AEZS) Actualités

Aeterna Zentaris Inc (AEZS)

Votre Hub pour des idées et discussions en direct en temps réel

AEZS Actualités

Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.

Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders

Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Aeterna Zentaris and Ceapro Complete Merger Transaction

Aeterna Zentaris and Ceapro Complete Merger Transaction

Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date

Aeterna Zentaris Announces Details Regarding Transaction with Ceapro

Aeterna Zentaris Reports First Quarter 2024 Financial Results

Aeterna Zentaris Announces Effective Date of Share Consolidation

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités